Biometro “Technology to diagnose various diseases with a drop of blood”
Biometro, a bio venture company together with the Finnish bio company Labmaster, announced on 16th that they have developed a technology that can identify various diseases using a drop of blood.
Biometro and Labmaster have been committed to joint R&D and commercialization of C-ECL(Cathodic-Electrochemiluminescence) technologies since 2015 and have been developing related technologies. Labmaster is a Finnish bio company that produces and sells immunoassay kits and diagnostic reagents.
Biometro claims that using this technology, a drop of blood from a patient can identify cancer, heart disease, and viral infections within five minutes.
Choong-kyung Kang, chief technology officer of Biometro, said, "Only two companies in the world that have developed ECL technology; Roche and Biometro/Labmaster." He also said, "Biometro/Labmaster's ECL technology has a similar level of accuracy and sensitivity to Roche’s."
The companies already have 10 patents registered including 8 US patents.
"Biometro/Labmaster's ECL technology has a sensitivity of close to one million times that of existing POCT diagnostic equipment, and it shows precision and accuracy similar to that of large-scale diagnostic equipment. We will be able to apply it in many fields in the future," said Gilnam Kang, the CEO of Biometro.
Biometro/Labmaster plan to launch products in the European market in the second half of this year, receiving CE certification for the European market for small in vitro diagnostic devices with this technology.
Labmaster Ltd launches new website
LABMASTER RAISES €6M IN FUNDING
Ltd, a Turku, Finland based biotechnology company raises €6M from a
company for the development of next generation proprietary detection
Labmaster is developing new technology for clinical, biochemical and
chemical analysis based on cathodic electrochemiluminescence (CECL). This
technology relates to the electrical excitation of label
substance/substances by hot electrons. Reactions occur on silicon based
electrodes coated with an insulating layer and utilize the resulting
electrochemiluminescence in analytical applications, especially in
bioaffinity assays such as immunoassays and DNA-probe assays.
One of the advantages of this technology is cost effectiveness achieved by
replacing expensive optics with low priced sophisticated electronics. This
technology is suitable for many kinds of laboratory instrumentation
applications, for example in clinical diagnostics from batch size analyzers
to disposable rapid tests (POCT). Labmaster owns the immaterial property rights for
this technology and has the strategy to further protect its findings related
to new applications.
2010: SITRA’s withdrawal and the company became privately owned
2006: CECL Feasibility Study for Pharmaceutical company and drug testing
2005: Labmaster PCR Amplification Kits and dry PCR mix were launched
2004: in MEDICA 2004 Labmaster’s own feasibility study on ultra-sensitive CRP assay was presented
2003: Labmaster Troponin I ELISA IVD kit was launched
Labmaster Troponin I ELISA IVD kit was launched and CE-marked in year 2005
2003: Labmaster brought onto the market Stable Troponin I antigen
Labmaster started manufacturing of unique products line of Phytoestrogen TR-FIA immunodiagnostic kits designed for the research of the dietary health
2002: Labmaster started sales of PPase soluble inorganic pyrophosphatase
1998: Labmaster stared to developed the panel for cardiac markers
Labmaster sold the clinical laboratory operations and started distribution of Cheshire Diagnostics Ltd - Autoimmuno diseases kit panel (e.g. Anti-Cardiolipin IgG, IgM & IgA ELISA) and later also Osteometer BioTech A/S osteoporosis kits
1991: Labmaster manufactured OEM products
In 1991 Labmaster manufactured OEM products, such as streptavidin coated -plates and DELFIA CRP Kits
1990: The IVD ELISA kit production was started
The IVD ELISA kit production was started with Total IgE, continued ß-2-Microglobulin, and later additions Anti-gliadin IgG and IgA, become the main products
1986: Monoclonal antibody production was started
Monoclonal antibody production was started for IgE, ß2M, CRP and PLA2
1985: Labmaster ltd, clinical research laboratory, was founded